AUergic conjunctivitis

Berdy GJ,Abelson MB, George MA, et al.AUergic conjunctivitis— a survey of new antihistamines. J Ocul Pharmacol 1991 7 313-324. [Pg.260]

Bielory L, Lien KW, Bigelsen S. Efficacy and tolerability of newer antihistamines in the treatment of aUergic conjunctivitis. Drugs 2005 65 215-228. [Pg.260]

CiprancU G, BuscagUa S, Cerqueti PM. Drug treatment of aUergic conjunctivitis. Drugs 1992 43 154-176. [Pg.260]

Easty DL, Rice NSA, Jones BR. CUnical trials of topical sodium cromoglycate in aUergic conjunctivitis. CUn AUergy 1972 2 99-107. [Pg.260]

Elena PP,AmarT, Fetz A, et al. Comparison of efficacy between ketotifen and olopatadine eye drops in aUergic conjunctivitis. Invest Ophthalmol Vis Sci 1998 39 S949. [Pg.260]

Friedlaender MH. Update on aUergic conjunctivitis. Rev OphthaUnol March, 1997 25(l) 92-98. [Pg.260]

Galindez OA, Kaufman HE. Coping with the itchy-burnies the management of aUergic conjunctivitis. Ophthalmology 1996 103 1335-1336. [Pg.260]

Ganz M, KoU E, Gausche J, Detjen, et al. Ketotifen fumarate and olopatadine hydrochloride in the treatment of aUergic conjunctivitis a real-world comparison of efficacy and ocular comfort.AdvTher 2003 20 79-91. [Pg.260]

Baddeley SM, Bacon AS, McGUl JI, et al. Mast ceU distribution and neutral protease expression in acute and chronic aUergic conjunctivitis. CUn Exp AUergy 1995 25 41-50. [Pg.572]

Ilyas H, Slonim CB, BrasweU GR, et al. Long-term safety of loteprednol etabonate 0.2% in the treatment of seasonal and perennial aUergic conjunctivitis. Eye Contact Lens 2004 30 10-13. [Pg.573]

Montan PG, van Hage-Hamsten M. EosinophU cationic protein in tears in aUergic conjunctivitis. Br J Ophthalmol 1996 80 556-560. [Pg.573]

Netland PA, Leahy C, Krenzer KL. Emedastine ophthalmic solution 0.05% versus levocabastine ophthalmic suspension 0.05% in the treatment of aUergic conjunctivitis using the conjunctival aUergen chaUenge model. Am J Ophthalmol 2000 130 717-723. [Pg.573]

Raizman MB, Rothman JS, Maroun F, Rand WM. Effect of eye rubbing on signs and symptoms of aUergic conjunctivitis in cat-sensitive individuals. Ophthalmol 2000 107 2158-2161. [Pg.573]

SecchiA, LeonardiA, Discepola M, et al.An efficacy and tolerance comparison of emedastine difumarate 0.05% and levocabastine hydrochloride 0.05% reducing chemosis and eyeUd sweUing in subjects with seasonal aUergic conjunctivitis. Acta OphthaUnol Scand 2000 78 48-51. [Pg.573]

BreakyAS, Cinotti AA, Hirshman M, et al.A double-blind, multicenter controUed trial of 0.25% oxymetazoUne ophthalmic solution in patients with aUergic and non-infectious conjunctivitis. Pharmatherapeutica 1980 2 353-356. [Pg.260]

Duzman E,Warman A,Warman R. Efficacy and safety of topical oxymetazoUne in treating aUergic and environmental conjunctivitis. Ann Ophthalmol 1986 18 28-31. [Pg.260]

AUergic reactions (Ud swelling, conjunctivitis, localized angioneurotic edema, exfoliative dermatitis) myopia. [Pg.756]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...